Physician profile
Manuel A Ojeda
NPI 1952333775
$5,527.36
in general payments reported to CMS, 2019-2025
10 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $846 · 2021: $1,668 · 2022: $915 · 2023: $452 · 2024: $745 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,313.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,202.55 | 2020-2024 | Jot Dx, Gallant, Assurity |
| Medtronic, INC. | $1,133.97 | 2021-2024 | Symplicity G3, Micra, Linq II |
| Sunovion Pharmaceuticals INC. | $792.54 | 2019-2020 | |
| Medtronic Vascular, INC. | $481.57 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $293.90 | 2022-2023 | Ingrezza |
| Boston Scientific Corporation | $274.16 | 2022-2025 | General - Brady |
| Janssen Pharmaceuticals, INC | $230.18 | 2021-2022 | |
| Abbvie INC. | $57.37 | 2021-2022 | |
| Allergan, INC. | $48.79 | 2019 | |
| Osiris Therapeutics INC. | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Ojeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.